Search by

Alcami Corporation

brand-profile-thumb

Company Headquarters

2320 Scientific Park Drive, Wilmington, NC, 28405, US

Driving Directions Phone: View Phone

Company Description

Alcami is a US contract development and manufacturing organization with 45+ years of experience advancing pharmaceuticals and biologics from development to delivery. Alcami provides fully integrated lab services, drug product manufacturing, and cGMP pharma storage and support services including calibration, validation and environmental monitoring.

Request more information from Alcami Corporation

Categories from Alcami Corporation

Content From Alcami Corporation

Ebook

Parental Market Trends

Gain insights into the parenteral and fill-finish manufacturing markets, opportunities, and recent investments in the space.

Released By Alcami Corporation

Case Studies

CASE STUDY: OSD FORMULATION DEVELOPMENT

Alcami used a Gerteis Mini-Pactor® roller compactor to develop a capsule formulation and critical processing parameters at the target dosage in record time.

Released By Alcami Corporation

News Releases

Alcami Appoints Timothy Compton As Chief Business Officer

25-year industry professional brings a track record of leading high-performing, client-centered business teams.

Released By Alcami Corporation

News Releases

Alcami Expands Parenteral Operations With Additional Investment

A $31 million investment will expand its sterile development and manufacturing operation in Charleston, SC.

Released By Alcami Corporation

News Releases

Alcami Announces Parenteral Operations Leadership Appointments

Chad Bovero, James Fife, and Tobin Cowart promoted to senior leadership team.

Released By Alcami Corporation

News Releases

Pharmather Engages Alcami For Clinical And Commercial Manufacturing Of Novel Ketamine Products

Alcami to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3 clinical studies and global commercialization.

Released By Alcami Corporation

News Releases

On-Demand Lab Open House

Sign up to get a close-up look at our US network of laboratories and hear about our expansion plans.

Released By Alcami Corporation

News Releases

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

The agreement represents another step toward the proprietary manufacturing, formulation, and delivery of products for Tryp’s PFNTM program.

Released By Alcami Corporation

News Releases

On-Demand Webinar: Microbial In-Use Studies

In this webinar, Alcami’s Brent Harlow will guide you through the necessity of these studies and how to successfully perform them for FDA approval.

Released By Alcami Corporation

Case Studies

QBD Addresses API Supply in Orphan Drug Formulation

Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process.

Released By Alcami Corporation

White Papers / Tech Papers

Host Cell Impurities, Bioassays, Micro-Flow Imaging

WHO, FDA and the European Pharmacopoeia have established strict regulatory guidelines to guarantee product quality in biologics.

Released By Alcami Corporation

News Releases

Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer

He succeeds Walter J. Kaczmarek III, who is stepping down as Chief Executive Officer.

Released By Alcami Corporation

Literature / Brochures

The Alcami Advantage

Wether you are a virtual start-up or a large organization, you and your patients deserve subject matter experts who take ownership of your program from clinical trals through commerical supply. Partnering with Alcami as your contract development and manufacturing organization connects you to a US-based team of dedicated professionals with over 40 years experience advancing […]

Released By Alcami Corporation

White Papers / Tech Papers

The Changing R&D Landscape

Emerging Technology Needs and Value Proposition for Strategic Partnerships with Contract Development and Manufacturing Organizations (CDMOs)

Released By Alcami Corporation

News Releases

Alcami Expands Oral Solid Capabilities with Investment in Wilmington, NC

Alcami, a leading United States-based contract development and manufacturing organization (CDMO), announced an additional $2 million investment to expand its oral solid development and manufacturing capabilities in Wilmington, NC. The investment will add a Gerteis Mini-Pactor® roller compactor and low humidity suites to Alcami’s existing 140,000 square foot campus in Wilmington, NC. The expansion, which is on track to be completed in the first […]

Released By Alcami Corporation

White Papers / Tech Papers

Structural Characterization of Biologics Using High-Resolution Mass Spectrometry

High-resolution mass spectrometry is a key component in the characterization of novel biologics and biosimilars.

Released By Alcami Corporation

White Papers / Tech Papers

The Importance of Food Studies in Pharmaceutical Development

Alternate methods of administering solid oral formulations are necessary to meet the needs of all patients.

Released By Alcami Corporation

Related Content